
    
      THIS IS A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY PLANNING TO ENROL 626
      SUBJECTS AFFECTED BY BACTERIAL VAGINOSIS.

      PRIMARY ENDPOINT:

      TO COMPARE THE EFFICACY OF TWO DOSES (25 MG AND 100 MG) OF RIFAXIMIN VAGINAL TABLETS VERSUS
      PLACEBO IN SUBJECTS WITH BACTERIAL VAGINOSIS

      SECONDARY ENDPOINT:

      TO COMPARE THE EFFICACY OF TWO DOSES (25 MG AND 100 MG) OF RIFAXIMIN VAGINAL TABLETS VERSUS
      METROGEL VAGINAL IN SUBJECTS WITH BACTERIAL VAGINOSIS.
    
  